This study synthesized and evaluated a series of novel 1,3,5-trisubstituted-1H-pyrazolo[3,4-d]thiazole derivatives (5a, 5b, 6a, 6b, and 7) for their cytotoxic, anti-inflammatory, and anticancer properties. The cytotoxic activity of these derivatives was evaluated against MCF-7 and HepG2 cell lines. Compound 6b demonstrated the most potentanticancer activity, with IC50 values of 15.57 ± 2.93 µg/mL for MCF-7 cells and 43.72 ± 1.90 µg/mL for HepG2 cells, demonstrating greater efficacy than doxorubicin. Mechanistic studies revealed that compound 6b induced S-phase arrest in MCF-7 cells and G1/S-phase arrest in HepG2 cells, along with a significant increasein apoptosis rates in the treated cancer cells. Moreover, compound 6b demonstrated significant VEGFR-2 inhibition, surpassing the efficacy of sorafenib. Compounds 5b and 6b demonstrated significant anti-inflammatory activity in RAW264.7 macrophage cells, as indicated by the decrease in nitric oxide (NO) production and the downregulation of proinflammatory cytokines, such as IL-1β, IL-6, and TNF-α. The derivatives exhibited no cytotoxicity towards normal cell lines (MCF-10A, THLE-2, and Vero cells), as validated by MTT assays. Docking studies elucidated the interaction mechanism between the compounds and the enzyme receptors. These findings demonstrate compound 6b as a promising candidate for the development of dual-function anticancer and anti-inflammatory agents.
Read full abstract- Home
- Search
Year
Publisher
Journal
1
Institution
Institution Country
Publication Type
Field Of Study
Topics
Open Access
Language
Reset All
Filter 1
Cancel
Year
Publisher
Journal
1
Institution
Institution Country
Publication Type
Field Of Study
Topics
Open Access
Language
Reset All
Filter 1
Export
Sort by: Relevance